For the quarter ended June 2026, Jazz Pharmaceuticals (JAZZ) reported revenue of $1.21 billion, up 15.6% over the same period last year. EPS came in at $5.71, compared to -$8.25 in the year-ago quarter.
The reported revenue represents a surprise of +9.33% over the Zacks Consensus Estimate of $1.11 billion. With the consensus EPS estimate being $6.04, the EPS surprise was -5.46%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Jazz performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Total revenues- Oncology- Total: $362.3 million compared to the $347.46 million average estimate based on six analysts. The reported number represents a change of +32.2% year over year.
- Total revenues- Oncology- Defitelio/defibrotide: $62 million versus the five-analyst average estimate of $48.74 million. The reported number represents a year-over-year change of +28.9%.
- Total revenues- Neuroscience- Oxybate- Xywav: $471.2 million versus the five-analyst average estimate of $433.17 million. The reported number represents a year-over-year change of +13.5%.
- Total revenues- Neuroscience- Epidiolex/Epidyolex: $292.1 million compared to the $270.84 million average estimate based on five analysts. The reported number represents a change of +16% year over year.
- Total revenues- Neuroscience- Oxybate (Xywav & Xyrem): $501.7 million versus $454.62 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +11.3% change.
- Total revenues- Oncology- Rylaze/Enrylaze: $99.5 million versus the five-analyst average estimate of $104.43 million. The reported number represents a year-over-year change of -1.2%.
- Total revenues- Oncology- Vyxeos: $31.4 million versus the five-analyst average estimate of $39.5 million. The reported number represents a year-over-year change of -30%.
- Total revenues- Oncology- Zepzelca: $105.8 million compared to the $93.38 million average estimate based on five analysts. The reported number represents a change of +41.9% year over year.
- Revenues- Product sales, net: $1.16 billion compared to the $1.08 billion average estimate based on five analysts. The reported number represents a change of +17.3% year over year.
- Total revenues- Oncology- Ziihera: $15.4 million compared to the $16.52 million average estimate based on five analysts.
- Total revenues- Modeyso: $48.2 million compared to the $46.79 million average estimate based on five analysts.
- Revenues- Royalties and contract revenues: $52.2 million versus the five-analyst average estimate of $30.8 million. The reported number represents a year-over-year change of -13.2%.
View all Key Company Metrics for Jazz here>>>
Shares of Jazz have returned +3.9% over the past month versus the Zacks S&P 500 composite's +0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
